Ribo Life Science Co., Ltd. (Ribo or the Company, stock code: 06938.HK), a leading company in small interfering RNA (siRNA) ...

Ribo's IPO is aiming to raise around HKD 1.59 billion (around $205 million) through the sale of 27.5 million shares at HKD 57 ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

Arrowhead Pharmaceuticals has received authorisation from Health Canada for its small interfering RNA (siRNA) medicine, ...

Sarepta Therapeutics (SRPT) recently submitted a clinical trial application in New Zealand for SRP-1005, its first-in-human small interfering RNA therapy targeting Huntington's Disease, highlighting ...

In addition to its Chinese R&D and manufacturing centers in Beijing and Suzhou, Ribo also set up a subsidiary, Ribocure AB, ...

Bayer & Soufflé Therapeutics enter strategic collaboration to advance cell-specific heart-targeted siRNA therapy: Berlin, Germany Friday, January 9, 2026, 09:00 Hrs [IST] Bayer a ...

Please provide your email address to receive an email when new articles are posted on . In this video, Yancy, a professor and chief of cardiology at Northwestern University Feinberg School of Medicine ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...